TG Therapeutics, Inc. (NASDAQ:TGTX) was the recipient of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 15,880,967 shares, a drop of 11.2% from the November 15th total of 17,893,222 shares. Currently, 28.2% of the shares of the stock are sold short. Based on an average trading volume of 1,400,762 shares, the days-to-cover ratio is presently 11.3 days.

Shares of TG Therapeutics (TGTX) opened at $8.20 on Thursday. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. analysts anticipate that TG Therapeutics will post -1.86 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its stake in TG Therapeutics by 44.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in TG Therapeutics by 152.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares during the last quarter. Dupont Capital Management Corp acquired a new stake in TG Therapeutics during the 2nd quarter worth $258,000. Ameriprise Financial Inc. boosted its stake in TG Therapeutics by 150.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after purchasing an additional 166,434 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in TG Therapeutics by 20.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after purchasing an additional 398,916 shares during the last quarter. 50.45% of the stock is currently owned by institutional investors.

TGTX has been the topic of a number of research analyst reports. B. Riley initiated coverage on shares of TG Therapeutics in a research note on Friday, December 1st. They issued a “buy” rating and a $21.50 price target on the stock. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. HC Wainwright reissued a “buy” rating and issued a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $25.50.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/14/tg-therapeutics-inc-tgtx-short-interest-update.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.